Milestone Pharmaceuticals Launches RESET-PSVT Registry

Registry Study Design Presented at the Preventive Cardiovascular Nurses Association 2026 Cardiovascular Nursing Symposium Registry Study Design Presented at the Preventive Cardiovascular Nurses Association 2026 Cardiovascular Nursing Symposium

Milestone Pharmaceuticals has announced the launch of the RESET-PSVT registry, a significant initiative aimed at generating real-world evidence on the efficacy and safety of CARDAMYST (etripamil nasal spray) for patients experiencing paroxysmal supraventricular tachycardia (PSVT). This condition is characterized by episodes of rapid heart rate that can cause discomfort and symptoms such as palpitations and anxiety.

The RESET-PSVT registry is designed to collect data from a broad range of patients who use CARDAMYST, including those who have not had success with existing treatments. The data will be instrumental in understanding how effective CARDAMYST is in real-world settings, which often differ from clinical trials. Furthermore, the registry will help identify any potential safety issues associated with the nasal spray.

Milestone Pharmaceuticals recognizes the importance of real-world data in modern medicine, as it can provide insights that randomized controlled trials may not fully capture. The company aims to recruit diverse participants to reflect the various demographics and co-morbidities often present among patients with PSVT, ensuring that the findings from the registry are applicable to a wider patient population.

Patients enrolled in the registry will be monitored and followed over time, with details about their health status and experiences with CARDAMYST meticulously recorded. This longitudinal approach allows researchers to assess not only the immediate outcomes of using the spray but also its long-term effects.

The study will include a variety of endpoints, including the frequency of PSVT episodes, patient-reported outcomes, and any adverse events experienced while using CARDAMYST. By focusing on these metrics, Milestone Pharmaceuticals hopes to demonstrate not only the drug's clinical performance but also its overall impact on the quality of life for patients with PSVT.

Cardiac arrhythmias, including PSVT, are a common issue faced by many individuals. Traditional treatment options often include medications, catheter ablation, and lifestyle modifications. However, the introduction of CARDAMYST represents a novel approach to the management of PSVT, providing patients with a non-invasive option to terminate episodes quickly.

As the registry progresses, Milestone Pharmaceuticals plans to share findings with the medical community and stakeholders to foster understanding and adoption of CARDAMYST as a reliable treatment option for PSVT. Additionally, the data collected may open avenues for future research and development aimed at enhancing care for patients with arrhythmias.

The launch of the RESET-PSVT registry reflects Milestone Pharmaceuticals' commitment to improving patient outcomes through evidence-based medicine. By prioritizing real-world evidence, they are striving to ensure that therapies like CARDAMYST meet the needs and expectations of patients living with PSVT.